a Spanish oncologist, principal investigator of an international study showing improvement in the treatment of lung cancer
-The publication of the article in The Lancet Oncology reveals the high level of Spanish research.
-The Dr. Luis Paz-Ares, head of the Oncology medical of the Hospital Virgen del RocÃo in Sevilla, first author of the publication of the study.
-Six Spanish centres participated in the Paramount Studio.
Spain, March 2012.- Publish in a scientific journal is a recognition of a job well done that only some researchers have throughout his career. Hence the importance that the prestigious magazine The Lancet Oncology has published the results of this study with a Spanish oncologist, as first author, in its March issue.
It is of Dr. Luis Paz-Ares, head of the Oncology medical of the Hospital Virgen del RocÃo in Sevilla, who in this article collects the results of the Paramount Studio, which has shown an increase in the free progression in patients with lung cancer survival not not scaly advanced NSCLC treated with pemetrexed (Alimta ®) of maintenance. This type of lung cancer is the most frequent (85-90% of all lung tumors are not microcÃticos1).
Thus, the median (since the beginning of the maintenance) progression-free survival is greater (HR: 0.62) in the Group of pemetrexed (4,1 months) than in the placebo (2.8 months) group. According to the preliminary results, since that starts the maintenance, the median overall survival of patients who was administered that pemetrexed is 13.9 months, while the placebo group is 11.1 months. The follow-up to the study is kept until at least 390 events occur, and can perform mature analysis (and final) survival of the essay.
Lung cancer has a high rate of mortality despite current treatments, which is why any progress is relevant for these patients. In this case the progress is significant in terms of efficacy, and toxicity profile is also particularly favourable ”, says Dr. Paz-Ares.
The publication of this article confirms the quality of the research work carried out in Spain. In total, six Spanish centres participated in the development of the study.
About Lilly Oncology
For more than four decades, Lilly Oncology, a division of Lilly, is dedicated to presenting innovative solutions that improve the care of patients with cancer. Because there are no two equal cancer patients, Lilly Oncology is committed to the development of new approaches to treatment. Pair
on Lilly
Lilly, a company based on innovation, is developing one growing portfolio of pharmaceutical products by applying the research more toe made both by its own laboratories worldwide and through collaborations with prestigious scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers to some of the most urgent medical needs in the world through the supply of drugs and information.
1 American Cancer Society, “What Is Non – Small Cell Lung Cancer?,” December 16, 2010, American Cancer Society, http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer, (April 20, 2011).
